Parse Biosciences announced that Tahoe Therapeutics selected its GigaLab platform to generate 300 million single cell sequencing profiles. Tahoe will use its Mosaic technology to produce samples from massive perturbation arrays. Moreover, Parse will apply its Evercode chemistry and automation to deliver the largest perturbation-focused single-cell sequencing dataset ever created. This project strengthens both companies’ roles in large-scale single-cell sequencing innovation.
GigaLab Strengthens High-Throughput Single Cell Capabilities
Parse’s GigaLab supports million- to hundred-million-cell projects through high-capacity liquid handling and standardized workflows. Additionally, its end-to-end QC ensures reproducible datasets at unprecedented scale. The Tahoe project ranks among the largest sequencing efforts handled at GigaLab. It also highlights rising industry demand for massive perturbation atlases capable of training modern AI models.
“This collaboration demonstrates how scalable single-cell technology can meet the demands of modern drug discovery,” said Charlie Roco, PhD, Chief Technology Officer and Co-founder at Parse Biosciences. “By combining our GigaLab platform with Tahoe’s perturbation engine, we are enabling a dataset that can power the next generation of AI models, changing how therapies are discovered.”
Tahoe Expands Its Lead in Perturbation-Based Drug Discovery
The 300-million-cell effort expands Tahoe’s leadership in building foundation-scale perturbation datasets. These datasets show how drugs, targets, and disease conditions interact across diverse biological systems. Tahoe’s Mosaic platform uniquely enables such
high-dimensional datasets, which support virtual cell models that predict therapeutic response and patient variability.
Traditional discovery pipelines often use datasets lacking broad perturbation diversity. Consequently, predictive AI systems struggle to capture biological complexity. Tahoe’s datasets will instead include:
- Multiple tissue types and disease models
- Thousands of compounds and genome-wide perturbations
- Pathway-specific and cell-type signatures at massive depth
- High-resolution insights into mechanism, plasticity, and drug response
These features allow Tahoe to uncover new mechanisms, identify unexpected interactions, and reveal therapeutic opportunities often missed in standard in vitro systems.
“Scaling single cell perturbation data is essential for building AI models that understand human biology,” said Johnny Yu, CSO of Tahoe Therapeutics. “Leveraging Parse’s GigaLab, we’re able to perform single cell sequencing on samples generated from our Mosaic technology at unprecedented depth and diversity, moving us closer to scale of foundational datasets that power our virtual cell models, which can predict therapeutic outcomes across patients and diseases.”
Partnership Signals a New Era in Data-Driven Therapeutics
This collaboration underscores a shift in life sciences. The next generation of therapeutic discovery requires data at scales achievable only by a few expert platforms. Parse’s GigaLab continues to define what is technically possible in large-scale single cell biology. Furthermore, it enables companies like Tahoe to develop AI systems grounded in richer biological context than ever before.
Explore HealthTech News for the latest breakthroughs in healthcare technology and expert insights driving the future of digital health innovation!
News Source: Businesswire.com
